EryPharm, a spin-off venture from Sorbonne University, is the entrepreneurial branch of the academic research conducted by the team led by Professor Luc Douay, who pioneered the different fundamental research stages (see publications):
2002
Creation of the concept of cultured red blood cells (cRBC) in animals
2005
In vitro production of cRBC from human hematopoietic stem cells (HSC)
2011
First cRBC injection in human: to validate the concept and evidence greater transfusion efficacy of cRBC versus native RBC
2015
Determination of the basic principles of mass production technology
2016
Creation of EryPharm
2020
Overcoming the final technical hurdles to initiating scale-up
Investment in a new pharmaceutical production site
2022
Preclinical trials: to confirm the absence of product toxicity
2023
First clinical trial: to confirm the benefits of cRBC
Continuation of clinical trials
Industrial scale-up
2030
cRBCs available for patients
